Curated News
By: NewsRamp Editorial Staff
November 11, 2026

Quantum BioPharma Approves Key Resolutions, Closes Private Placement

Discuss on Substack
Original Source

TLDR

  • Quantum BioPharma's insider Class A share placement boosts aggregate voting power to 68.22%, tightening control ahead of potential consolidation and name change.
  • Quantum BioPharma issued 26 Class A multiple voting shares at C$3.11 to two insider entities, lifting their combined voting power from 57.01% to 68.22%.
  • Quantum BioPharma advances its MS and alcohol misuse drug pipeline while shareholders approve governance measures and a working capital raise.
  • Quantum BioPharma sold 26 multiple voting shares for C$80.86 total, with insiders each taking 13 shares and voting power nearing 70%.

Impact - Why it Matters

The voting power shift to 68.22% concentrates control among insiders, potentially enabling faster strategic decisions but raising governance concerns for minority shareholders. The approved share consolidation and name change could improve the company's market perception and appeal to institutional investors. Quantum's diverse pipeline, including Lucid-MS for multiple sclerosis and UNBUZZD for alcohol misuse, positions it in high-growth markets with significant unmet needs. The royalty agreement with Unbuzzd provides a long-term revenue stream, with potential for up to $250 million in payments and ongoing royalties. These developments are crucial for investors tracking Quantum's progress in neurodegenerative and metabolic disorders.

Summary

Quantum BioPharma (NASDAQ: QNTM) reported the results of its November 10, 2026, annual general and special meeting of shareholders and the closing of a non-brokered private placement of 26 Class A multiple voting shares on November 9. Shareholders elected all five director nominees, reappointed MNP LLP as auditor, and approved several resolutions, including authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1, and a potential corporate name change. The board retains discretion over implementing these authorized measures.

The company issued 26 Class A multiple voting shares at C$3.11 per share, generating gross proceeds of C$80.86. Xorax Family Trust, associated with CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by director Anthony Durkacz, each acquired 13 shares. Following the placement, the aggregate voting power of Class A multiple voting shares increased from approximately 57.01% to 68.22%. The transaction was completed under shareholder authorization granted in 2025, with proceeds designated for general working capital purposes. To view the full press release, visit https://ibn.fm/UagXR.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Approves Key Resolutions, Closes Private Placement

Blockchain registration record for this content